A contribution to the differential diagnostics of sclerosing cholangitides

Česká verze

Authors: Martin Blaho; Petr Dítě; Martina Bojková; Martin Rydlo; Tomáš Kupka; Pavel Svoboda; Pavel Klvaňa; Arnošt Martínek
Authors place of work: Gastroenterologické oddělení Interní kliniky LF OU a FN Ostrava
Published in the journal: Vnitř Lék 2017; 63(1): 50-55
Category: Přehledné referáty

Summary

Sclerosing cholangitides represent a group of chronic biliary obstructive diseases which include primary sclerosing cholangitis (PSC), IgG4 associated sclerosing cholangitis (IgG4-SC) and secondary sclerosing cholangitis (SSC). The manifestations of the diseases are similar, but their asymptomatic course is also frequent. IgG4-SC belongs to the group of IgG4 associated diseases and it is the most frequently related to type 1 autoimmune pancreatitis. Diagnosing of IgG4-SC is based on typical histopathological images, shape changes revealed by diagnostic imaging, serological tests, concurrent impairment of other organs and response to therapy, where IgG4-SC responds well to treatment with corticoids, whereas the only possibility for the remaining units is endoscopic intervention or liver transplantation. Secondary sclerosing cholangitis may develop as a result of many different insults affecting the biliary tree. Among them, the most frequently described include long-lasting biliary obstruction, surgical injury of the biliary tree, and ischemic cholangitis in liver allotransplants or recurrent pancreatitis. We use serological and imaging examination in PSC diagnostics, sometimes we have to resort to liver biopsy. PSC is to a significant degree accompanied by the presence of idiopathic bowel disease, typically ulcerative colitis. As a result, PSC may lead to cirrhosis of the liver and it is a precancerous condition of several malignancies. With regard to variable locations of the biliary tree injuries concerning the aforementioned units, also certain malignancies in subhepatic landscape need to be considered in the differential diagnosis: pancreatic cancer and cholangiogenous carcinoma.

Key words:
genetic factors – IBD – IgG4 cholangitis – liver transplantation – bile duct cancer – ursodeoxycholic acid – primary sclerosing cholangitis – secondary cholangitis – sclerosing cholangitis

Zdroje

1. Lindkvist B, Benito de Valle M, Gullberg B et al. Incidence and prevalence of primary sclerosing cholangitis in a defined adult population in Sweden. Hepatology 2010; 52(2): 571–577. Dostupné z DOI: <http://dx.doi.org/10.1002/hep.23678>.

2. Bambha K, Kim WR, Talwalkar J, et al. Incidence, clinical spectrum, and outcomes of primary sclerosing cholangitis in a United States community. Gastroenterology 2003; 125(5): 1364–1369.

3. Kaplan GG, Laupland KB, Butzner D et al. The burden of large and small duct primary sclerosing cholangitis in adults and children: a population-based analysis. Am J Gastroenterol. 2007; 102(5): 1042–1049.

4. Tanaka A, Tazuma S, Okazaki K et al. Nationwide survey for primary sclerosing cholangitis and IgG4-related sclerosing cholangitis in Japan. J Hepatobiliary Pancreat Sci 2014; 21(1): 43–50. Dostupné z DOI: <http://dx.doi.org/10.1002/jhbp.50>.

5. Zen Y, Harada K, Sasaki M et al. IgG4-related sclerosing cholangitis with and without hepatic inflammatory pseudotumor, and sclerosing pancreatitis-associated sclerosing cholangitis: do they belong to a spectrum of sclerosing pancreatitis? Am J Surg Pathol 2004;28(9):1193–1203.

6. Ghazale A, Chari ST, Zhang L et al. Immunoglobulin G4-associated cholangitis: clinical profile and response to therapy. Gastroenterology 2008; 134(3): 706–715. Dostupné z DOI: <http://dx.doi.org/10.1053/j.gastro.2007.12.009>.

7. Maillette de Buy Wenniger LJ, Doorenspleet ME, Klarenbeek PL et al. Immunoglobulin G4+ clones identified by next-generation sequencing dominate the B cell receptor repertoire in immunoglobulin G4 associated cholangitis. Hepatology 2013; 57(6): 2390–2398. Dostupné z DOI: <http://dx.doi.org/10.1002/hep.26232>.

8. Hubers L, Doorenspleet M, Klarenbeek P et al. The IgG/IgG4 mRNA Ratio By Quantitative PCR Accurately Diagnoses IgG4-Related Disease and Predicts Treatment Response [abstract]. Arthritis Rheumatol 2015; 67(Suppl 10). Dostupné z WWW: <http://acrabstracts.org/abstract/the-iggigg4-mrna-ratio-by-quantitative-pcr-accurately-diagnoses-igg4-related-disease-and-predicts-treatment-response/>. [13.01.2017].

9. Molodecky NA, Kareemi H, Parab R et al. Incidence of primary sclerosing cholangitis: a systematic review and meta-analysis. Hepatology 2011; 53(5): 1590–1599. Dostupné z DOI: <http://dx.doi.org/10.1002/hep.24247>.

10. Porayko MK, Wiesner RH, LaRusso NF et al. Patients with asymptomatic primary sclerosing cholangitis frequently have progressive disease. Gastroenterology 1990; 98(6): 1594–1602.

11. Broome U, Olsson R, Loof L et al. Natural history and prognostic factors in 305 Swedish patients with primary sclerosing cholangitis. Gut 1996; 38(4): 610–615.

12. Chapman R, Fevery J, Kalloo A et al. Diagnosis and management of primary sclerosing cholangitis. Hepatology 2010; 51(2): 660–678. Dostupné z DOI:<http://dx.doi.org/10.1002/hep.23294>.

13. Soetikno RM, Lin OS, Heidenreich PA et al. Increased risk of colorectal neoplasia in patients with primary sclerosing cholangitis and ulcerative colitis: a meta-analysis. Gastrointest Endos 2002; 56(1): 48–54.

14. Penna C, Dozois R, Tremaine W et al. Pouchitis after ileal pouch-anal anastomosis for ulcerative colitis occurs with increased frequency in patients with associated primary sclerosing cholangitis. Gut 1996; 38(2): 234–239.

15. Wiesner RH, LaRusso NF, Dozois RR et al. Peristomal varices after proctocolectomy in patients with primary sclerosing cholangitis. Gastroenterology 1986; 90(2): 316–322.

16. Fevery J, Henckaerts L, Van Oirbeek R et al. Malignancies and mortality in 200 patients with primary sclerosering cholangitis: a long-term single-centre study. Liver Int 2012; 32(2): 214–222. Dostupné z DOI: <http://dx.doi.org/10.1111/j.1478–3231.2011.02575.x>.

17. Verdonk RC, Dijkstra G, Haagsma EB et al. Inflammatory bowel disease after liver transplantation: risk factors for recurrence and de novo disease. Am J Transplant 2006; 6(6): 1422–1429.

18. Marelli L, Xirouchakis E, Kalambokis G et al. Does the severity of primary sclerosing cholangitis influence the clinical course of associated ulcerative colitis? Gut 2011; 60(9): 1224–1228. Dostupné z DOI: <http://dx.doi.org/10.1136/gut.2010.235408>.

19. Navaneethan U, Venkatesh PG, Mukewar S et al. Progressive primary sclerosing cholangitis requiring liver transplantation is associated with reduced need for colectomy in patients with ulcerative colitis. Clin Gastroenterol Hepatol 2012;10(5): 540–546. Dostupné z DOI: <http://dx.doi.org/10.1016/j.cgh.2012.01.006>.

20. Bergquist A, Ekbom A, Olsson R et al. Hepatic and extrahepatic malignancies in primary sclerosing cholangitis. J Hepatol 2002; 36(3): 321–327.

21. Lindstrom L, Lapidus A, Ost A et al. Increased risk of colorectal cancer and dysplasia in patients with Crohn’s colitis and primary sclerosing cholangitis. Dis Colon Rectum 2011; 54(11):1392–7. Dostupné z DOI: <http://dx.doi.org/10.1097/DCR.0b013e31822bbcc1>.

22. Bergquist A, Lindberg G, Saarinen S et al. Increased prevalence of primary sclerosing cholangitis among first-degree relatives. J Hepatol 2005; 42(2): 252–256.

23. Karlsen TH, Franke A, Melum E et al. Genome-wide association analysis in primary sclerosing cholangitis. Gastroenterology 2010; 138(3): 1102–1111. Dostupné z DOI: <http://dx.doi.org/10.1053/j.gastro.2009.11.046>.

24. Melum E, Franke A, Schramm C et al. Genome-wide association analysis in primary sclerosing cholangitis identifies two non-HLA susceptibility loci. Nat Genet 2011; 43(1): 17–19. Dostupné z DOI: <http://dx.doi.org/10.1038/ng.728>.

25. Lichtman SN, Sartor RB. Hepatobiliary injury associated with experimental small-bowel bacterial overgrowth in rats. Immunol Res 1991; 10(3–4): 528–531.

26. O’Mahony CA, Vierling JM. Etiopathogenesis of primary sclerosing cholangitis. Semin Liver Dis 2006; 26(1): 3–21.

27. Palmer KR, Duerden BI, Holdsworth CD. Bacteriological and endotoxin studies in cases of ulcerative colitis submitted to surgery. Gut 1980; 21(10): 851–854.

28. Borchers AT, Shimoda S, Bowlus C et al. Lymphocyte recruitment and homing to the liver in primary biliary cirrhosis and primary sclerosing cholangitis. Semin Immunopathol 2009; 31(3): 309–322. Dostupné z DOI: <http://dx.doi.org/10.1007/s00281–009–0167–2>.

29. Grant AJ, Lalor PF, Hubscher SG et al. MAdCAM-1 expressed in chronic inflammatory liver disease supports mucosal lymphocyte adhesion to hepatic endothelium (MAdCAM-1 in chronic inflammatory liver disease). Hepatology 2001; 33(5): 1065–1072.

30. Grant AJ, Lalor PF, Salmi M et al. Homing of mucosal lymphocytes to the liver in the pathogenesis of hepatic complications of inflammatory bowel disease. Lancet 2002; 359(9301): 150–157.

31. MacCarty RL, LaRusso NF, Wiesner RH et al. Primary sclerosing cholangitis: findings on cholangiography and pancreatography. Radiology 1983; 149(1): 39–44.

32. Dave M, Elmunzer BJ, Dwamena BA et al. Primary sclerosing cholangitis: meta-analysis of diagnostic performance of MR cholangiopancreatography. Radiology 2010; 256(2): 387–396. Dostupné z DOI: <http://dx.doi.org/10.1148/radiol.10091953>.

33. Kaltenthaler E, Vergel YB, Chilcott J et al. A systematic review and economic evaluation of magnetic resonance cholangiopancreatography compared with diagnostic endoscopic retrograde cholangiopancreatography. Health Technol Assess 2004; 8(10; iii): 1–89.

34. Burak KW, Angulo P, Lindor KD Is there a role for liver biopsy in primary sclerosing cholangitis? Am J Gastroenterol 2003; 98(5): 1155–1158.

35. Corpechot C, El Naggar A, Poujol-Robert A et al. Assessment of biliary fibrosis by transient elastography in patients with PBC and PSC. Hepatology 2006; 43(5): 1118–1124.

36. Wong GL. Transient elastography: Kill two birds with one stone? World J Hepatol 2013; 5(5): 264–274. Dostupné z DOI: <http://dx.doi.org/10.4254/wjh.v5.i5.264>.

37. Abd El Rihim AY, Omar RF, Fathalah W et al. Role of fibroscan and APRI in detection of liver fibrosis: a systematic review and meta-analysis. Arab J Gastroenterol 2013; 14(2): 44–50. Dostupné z DOI: <http://dx.doi.org/10.1016/j.ajg.2013.05.002>.

38. Triantos CK, Koukias NM, Nikolopoulou VN et al. Meta-analysis: ursodeoxycholic acid for primary sclerosing cholangitis. Aliment Pharmacol Ther 2011; 34(8): 901–910. Dostupné z DOI: <http://dx.doi.org/10.1111/j.1365–2036.2011.04822.x>.

39. Eaton JE, Silveira MG, Pardi DS et al. High-dose ursodeoxycholic acid is associated with the development of colorectal neoplasia in patients with ulcerative colitis and primary sclerosing cholangitis. Am J Gastroenterol 2011; 106(9): 1638–1645. Dostupné z DOI: <http://dx.doi.org/10.1038/ajg.2011.156>.

40. EASL Clinical Practice Guidelines: management of cholestatic liver diseases. J Hepatol 2009; 51(2): 237–267. Dostupné z DOI: <http://dx.doi.org/10.1016/j.jhep.2009.04.009>.

41. Hommes DW, Erkelens W, Ponsioen C et al. A double-blind, placebo-controlled, randomized study of infliximab in primary sclerosing cholangitis. J Clin Gastroenterol 2008; 42(5): 522–526. Dostupné z DOI: <http://dx.doi.org/10.1097/MCG.0b013e3181662426>.

42. [European Association for the Study of the Liver]. EASL Clinical Practice Guidelines: Liver transplantation. J Hepatol 2016; 64(2): 433–485. Dostupné z DOI: <http://dx.doi.org/10.1016/j.jhep.2015.10.006>.

43. Darwish Murad S, Kim WR, Harnois DM et al. Efficacy of neoadjuvant chemoradiation, followed by liver transplantation, for perihilar cholangiocarcinoma at 12 US centers. Gastroenterology 2012; 143(1): 88–98.e3. Dostupné z DOI: <http://dx.doi.org/10.1053/j.gastro.2012.04.008>.

44. Nakazawa T, Naitoh I, Hayashi K et al. Diagnosis of IgG4-related sclerosing cholangitis. World J Gastroenterol 2013; 19(43): 7661–7670. Dostupné z DOI: <http://dx.doi.org/10.3748/wjg.v19.i43.7661>.